Gujarat Kidney & Super Speciality Ltd.

As of June 30, 2026, Gujarat Kidney & Super Speciality Ltd. carries a market capitalization of 10.23B, placing it among publicly traded companies globally. Its enterprise value stands at 10.23B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Gujarat Kidney & Super Speciality Ltd. has 78.84M shares outstanding.

As of June 30, 2026, Gujarat Kidney & Super Speciality Ltd. trades at a trailing price-to-earnings ratio of 49.72.

As of June 30, 2026, Gujarat Kidney & Super Speciality Ltd. trades at an EV/EBITDA multiple of 33.87 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 9.89 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 40.98 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 10.23B versus a market cap of 10.23B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

Over the twelve months ended June 30, 2026, Gujarat Kidney & Super Speciality Ltd. recorded 49.11M in income tax expense. That works out to an effective tax rate of 20.32, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 241.68M, leaving 180.10M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 23, 2026. The 50-day moving average sits at 171.66, while the 200-day moving average is 132.14.

Over the twelve months ended June 30, 2026, Gujarat Kidney & Super Speciality Ltd. generated 1.03B in revenue and converted that into 180.10M in net income, yielding earnings per share of 2.79. EBITDA reached 301.93M, while operating income came in at 249.56M.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Gujarat Kidney & Super Speciality Ltd. posted a gross margin of 88.24, reflecting its pricing power and cost economics. The operating margin of 24.14 and net profit margin of 17.42 provide insight into operational efficiency.